From Innovation to Adoption: Why New GLP-1 Delivery Routes Require Human Factors and Training from Day One

Recent developments point to a future that goes beyond traditional injectable formats. New research and patent activity are exploring intranasal and pulmonary delivery routes for GLP-1 therapies, signaling a potential shift toward non-invasive administration options. Early data suggests promising performance characteristics in preclinical models, reinforcing the industry’s focus on improving both efficacy and accessibility.

But as the industry pushes forward with new delivery technologies, an important question remains:

What does this mean for patients?

Innovation Changes the Device. It Also Changes the Experience.

New delivery routes introduce new user interactions.

Moving from an auto-injector to a nasal or inhaled format may seem like a simplification on the surface. Removing the needle can reduce perceived barriers for some patients. But in reality, it introduces a completely different set of behaviors, expectations, and potential challenges.

Patients must now:

• Understand a new administration technique
• Learn how to position and activate the device correctly
• Coordinate inhalation or nasal delivery timing
• Interpret sensory feedback that differs from injection-based systems

These are not incremental changes. They represent a fundamental shift in how therapy is experienced and executed in the real world.

And with every new interaction comes the potential for variability.

The Risk: When Innovation Outpaces Usability

In clinical settings, therapies are often administered under guidance. In the real world, however, patients are responsible for their own success.

This is where innovation can encounter friction.

A delivery method that performs well in controlled studies may not translate seamlessly into consistent, correct use at home. Even small misunderstandings or technique deviations can impact:

• Dose delivery confidence
• Treatment adherence
• Patient satisfaction
• Ultimately, therapeutic outcomes

Non-invasive does not automatically mean intuitive.

In fact, unfamiliar formats can increase uncertainty, especially during the critical first dose experience.

The First Dose Defines What Comes Next

One of the most overlooked moments in therapy is the transition from prescription to real-world use.

For new delivery formats, that moment becomes even more critical.

Patients are not just starting a therapy. They are learning a completely new way to take it.

If the first experience is unclear, confusing, or unsuccessful, the downstream effects can be significant:

• Delayed therapy initiation
• Increased calls to support teams
• Reduced confidence in self-administration
• Higher likelihood of early abandonment

As delivery innovation accelerates, the margin for error during onboarding does not shrink. It expands.

Why Human Factors Must Be Built In Early

This is where human factors and user experience design become essential.

New delivery routes require more than engineering excellence. They require a deep understanding of how real people interact with devices in real environments.

Human factors insight helps identify:

• Where users may struggle with technique
• How instructions can be simplified and clarified
• Which design elements support or hinder correct use
• What types of feedback reinforce confidence during administration

By embedding this perspective early in development, teams can reduce risk before products ever reach patients.

It is not about fixing problems later. It is about preventing them from occurring in the first place.

Training Is No Longer Optional. It Is Foundational.

As delivery modalities evolve, training must evolve with them.

Instruction manuals alone are not enough to support confident self-administration, especially for novel formats like nasal or pulmonary delivery.

Patients benefit from:

• Hands-on practice before first use
• Clear, intuitive guidance tailored to real-world scenarios
• Reinforcement of correct technique
• Ongoing support beyond initial onboarding

Training solutions help bridge the gap between device design and patient success.

They transform uncertainty into confidence and intention into correct action.

Turning Innovation Into Real-World Success

The future of GLP-1 delivery is expanding. Intranasal and inhaled therapies represent an exciting step forward in improving access and patient choice.

But innovation alone does not drive outcomes.

Adoption does.

For new delivery formats to succeed, they must do more than work in theory. They must work in the hands of patients, consistently and confidently.

That requires a holistic approach:

• Human-centered design grounded in real-world behavior
• Training solutions that prepare patients before first use
• Onboarding experiences that build confidence from day one
• Ongoing support that reinforces adherence over time

At Noble, we believe that every advancement in drug delivery must be matched with an equal focus on the patient experience.

Because even the most advanced therapies can fall short if patients are not prepared to use them correctly.

Start with the Patient. Stay with the Patient.

As GLP-1 delivery continues to evolve, the opportunity is clear.

By integrating human factors, training, and patient engagement early in the development process, organizations can turn innovation into impact.

From first dose to long-term adherence, success is built on confidence.

And confidence starts with experience.